American society of clinical oncology/national comprehensive cancer network quality measures

被引:187
作者
Desch, Christopher E.
McNiff, Kristen K.
Schneider, Eric C.
Schrag, Deborah
McClure, Joan
Lepisto, Eva
Donaldson, Molla S.
Kahn, Katherine L.
Weeks, Jane C.
Ko, Clifford Y.
Stewart, Andrew K.
Edge, Stephen B. [1 ]
机构
[1] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
关键词
D O I
10.1200/JCO.2008.16.5068
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The National Cancer Policy Board recommended the creation of quality measures and a national reporting system in 1999. Representatives from the American Society of Clinical Oncology ( ASCO) and the National Comprehensive Cancer Network ( NCCN) collaborated to create metrics suitable for national performance measurement. Methods Content and methodology experts nominated by ASCO and NCCN met to select and refine metrics for breast, colon, and rectal cancer based on National Initiative for Cancer Care Quality and NCCN measures and NCCN and ASCO guidelines. Measures were selected based on their impact on disease free and overall survival, the degree to which opportunities for improvement exist, and the feasibility of data collection. Results Three breast cancer measures and four colorectal cancer measures were chosen. Measures for breast cancer included adjuvant hormone therapy for hormone receptor - positive tumors, chemotherapy for hormone receptor - negative cancer, and radiation after lumpectomy. Colorectal measures included adjuvant radiation and chemotherapy for rectal cancer, and adjuvant chemotherapy for colon cancer. All but one were recommended as accountability measures and one for quality improvement ( removal and examination of 12 or more lymph nodes in colon cancer). Specifications were developed for each measure using tumor registries as the data source. Conclusion ASCO/ NCCN measures can be implemented by health systems, provider groups or payors for improvement or accountability using local tumor registries to furnish data on staging and treatment.
引用
收藏
页码:3631 / 3637
页数:7
相关论文
共 42 条
[1]  
Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0
[2]  
*AM SOC CLIN ONC, QUAL ONC PRACT IN
[3]   American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer [J].
Benson, AB ;
Schrag, D ;
Somerfield, MR ;
Cohen, AM ;
Figueredo, AT ;
Flynn, PJ ;
Krzyzanowska, MK ;
Maroun, J ;
McAllister, P ;
Van Cutsem, E ;
Brouwers, M ;
Charette, M ;
Haller, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3408-3419
[4]   Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes [J].
Berger, AC ;
Sigurdson, ER ;
LeVoyer, T ;
Hanlon, A ;
Mayer, RJ ;
Macdonald, JS ;
Catalano, PJ ;
Haller, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8706-8712
[5]   The use of radiation as a component of breast conservation therapy in national comprehensive cancer network centers [J].
Buchholz, TA ;
Theriault, RL ;
Niland, JC ;
Hughes, ME ;
Ottesen, R ;
Edge, SB ;
Bookman, MA ;
Weeks, JC .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (03) :361-369
[6]  
CHANG CJ, 2007, JNCI-J NATL CANCER I, V99, P43
[7]   Completeness of information on adjuvant therapies for colorectal cancer in population-based cancer registries [J].
Cress, RD ;
Zaslavsky, AM ;
West, DW ;
Wolf, RE ;
Felter, MC ;
Ayanian, JZ .
MEDICAL CARE, 2003, 41 (09) :1006-1012
[8]  
*CTR MED MED SERV, QUAL ONC PRACT IN
[9]   Information on chemotherapy and hormone therapy from tumor registry had moderate agreement with chart reviews [J].
Du, XLL ;
Key, CR ;
Dickie, L ;
Darling, R ;
Delclos, GL ;
Waller, K ;
Zhang, D .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2006, 59 (01) :53-60
[10]  
Engstrom Paul F, 2005, J Natl Compr Canc Netw, V3, P492